VIP for Mast Cell Activation Syndrome

Candidate profile

Adults with diagnosed or clinically suspected mast cell activation syndrome (MCAS) — episodic mediator release affecting two or more organ systems (flushing, urticaria, GI distress, tachycardia, hypotension, wheezing, brain fog). Diagnosis requires consistent symptoms, documented mediator elevation during episodes, and response to mast cell-directed therapy.

Particularly relevant for MCAS patients with concurrent chronic inflammatory response syndrome (CIRS) or biotoxin illness, where VIP deficiency has been documented. The Shoemaker protocol positions VIP as a late-stage intervention.

Not appropriate as first-line MCAS treatment — optimize standard mast cell stabilizers, H1/H2 antihistamines, and leukotriene inhibitors first. Not appropriate for mastocytosis without hematology oversight.

Approach

Vasoactive intestinal peptide (VIP) is a 28-amino-acid endogenous neuropeptide with immunomodulatory, anti-inflammatory, and mast cell-stabilizing properties. It acts through two G-protein-coupled receptors — VPAC1 and VPAC2 — expressed on mast cells, macrophages, dendritic cells, and T cells.

VIP's relevance to MCAS involves several mechanisms:

• Direct mast cell stabilization: VPAC2 binding activates adenylyl cyclase, raising intracellular cAMP, which inhibits degranulation and reduces release of histamine, tryptase, prostaglandin D2, and leukotrienes
• NF-kB inhibition: Downregulates pro-inflammatory cytokine transcription (TNF-alpha, IL-6, IL-8), disrupting the feed-forward inflammatory loop that perpetuates MCAS flares
• Th1/Th2 rebalancing: Shifts immune tone away from Th2 dominance and promotes regulatory T cell differentiation, addressing the dysregulation driving chronic mast cell activation
• Mucosal immune regulation: Expressed abundantly in the enteric nervous system and respiratory epithelium, VIP acts as a natural brake on mucosal immune activation
• Neuroprotection: Anti-neuroinflammatory effects may address MCAS-associated brain fog

Protocol design

Peptide: VIP (28-amino-acid sequence)

Primary route: Intranasal — delivers VIP to the nasal mucosa and respiratory tract with partial systemic absorption

Dose: 50 mcg per administration (one spray per nostril)

Frequency: 2-4 times daily, starting at the lower frequency

Duration: 4-12 weeks initial trial; the Shoemaker protocol recommends 30 days with reassessment.

Subcutaneous alternative: 50-100 mcg SubQ once daily — more reliable systemic delivery but less commonly used for MCAS. Intranasal is preferred for its local mucosal effects.

Shoemaker protocol sequencing: In the CIRS context, VIP is the final step — introduced only after cholestyramine biotoxin binding, MARCoNS clearance, and normalization of inflammatory markers (C4a, TGF-beta-1, MMP-9, ADH/osmolality, VEGF). Starting VIP before addressing upstream factors may yield incomplete results.

Starting low: Begin at 50 mcg twice daily. VIP is a potent vasodilator; some patients experience initial headache, flushing, or nasal congestion. Increase to 3-4 times daily after 1-2 weeks if tolerated.

Expected timeline

Days 1-7: Vasodilatory side effects (flushing, headache, nasal congestion) in ~20-30% of patients, typically resolving within 3-5 days. Some report early cognitive improvement and reduced anxiety.

Weeks 1-3: Gradual reduction in MCAS symptom frequency. Flushing, urticaria, and GI symptoms lessen as cumulative mast cell stabilization reduces degranulation and inflammatory priming. Sleep may improve as histamine-driven awakenings decrease.

Weeks 4-8: More substantial improvement. Shoemaker's clinical series reports normalization of C4a, TGF-beta-1, and VEGF within 1-2 months. Reassess mediator levels. Patients often report improved exercise tolerance and cognition.

Weeks 8-12: Consolidation. Some patients reduce frequency or shift to as-needed use; others require ongoing daily dosing. Retest inflammatory markers at 30 days and at course end.

Monitoring markers

• Serum tryptase at baseline, weeks 4 and 8 (may be normal in many MCAS patients)
• Plasma histamine or 24-hour urine N-methylhistamine at baseline and week 8
• 24-hour urine prostaglandin D2 (or 11-beta-prostaglandin F2-alpha) at baseline and week 8 — the most specific mast cell mediator
• Serum chromogranin A at baseline and week 8
• C4a complement at baseline and week 4 (particularly relevant in CIRS)
• TGF-beta-1 and VEGF at baseline and week 4
• VIP serum level at baseline (low endogenous VIP provides rationale for replacement)
• Blood pressure at each visit (monitor for hypotension)
• Symptom diary — daily tracking across organ systems

Evidence assessment

The evidence rests on strong basic science and clinical case series, but lacks randomized controlled trials.

Basic science is well-established: VIP's mast cell-stabilizing effects via VPAC receptors and cAMP elevation are demonstrated in multiple in vitro and animal studies, and its anti-inflammatory effects are among the most studied of any neuropeptide.

Clinical evidence comes primarily from Ritchie Shoemaker's clinical series on CIRS, where intranasal VIP normalized inflammatory markers and improved symptoms in a majority of patients — but from open-label practice without placebo controls or standardized outcomes.

No RCTs exist for VIP in MCAS. The closest controlled data comes from small VIP trials in pulmonary arterial hypertension and preclinical IBD studies — supportive but not direct MCAS validation. Documented VIP deficiency in CIRS/MCAS provides a replacement rationale, but low levels do not prove replacement corrects the dysfunction.

Important considerations

• Not first-line: Optimize H1/H2 antihistamines, cromolyn, ketotifen, and montelukast first
• Vasodilatory side effects: Headache, flushing, and hypotension in 20-30%; potentially problematic with POTS or autonomic dysfunction
• Pulmonary concerns: Potent pulmonary vasodilator; baseline pulmonary function testing is prudent
• MARCoNS clearance required in the Shoemaker protocol before starting VIP
• Storage: Requires refrigeration; degrades with heat exposure
• No regulatory approval: Not FDA-approved for MCAS; compounding pharmacy only
• Complex diagnosis: MCAS has evolving criteria — ensure specialist workup before pursuing peptide interventions
• Educational purposes only. Do not initiate, modify, or discontinue treatment without consulting a qualified healthcare provider